- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Methergine
Synonyms :
methylergometrine
Class :
Ergot Derivatives
Dosage Forms & Strengths
Tablet
0.2mg
Injectable solution
0.2mg/ml
Administer 0.2mg intramuscularly or intravenously every 2 to 4 hours whenever necessary, then administer 0.2 to 0.4mg orally every 6 to 8 hours whenever necessary for 2 to 7 days.
Do not exceed more than 5 doses.
Due to the risk of hypertension and cerebrovascular accident, only administer intravenously in an emergency.
Monitor blood pressure for more than one minute after administration.
Refractory Cluster Headache (Off-label)
Administer 0.2 mg orally thrice or four times a day. Do not continue for more than 6 months.
Not recommended
Refer adult dosing
may enhance the serum concentration of each other when combined
may increase the vasoconstricting effect of Ergot Derivatives
may increase the vasoconstricting effect of Ergot Derivatives
may increase the vasoconstricting effect of Ergot Derivatives
may increase the vasoconstricting effect of Ergot Derivatives
may increase the vasoconstricting effect of Ergot Derivatives
may increase the vasoconstricting effect of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may decrease the vasodilatory effect when combined with nitroglycerin
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may increase the vasoconstriction effect
may have an increased vasoconstricting effect when combined with alpha-/beta-agonists
may enhance the serum concentration of CYP3A4 inhibitors
may increase the levels of serum concentration of ergot derivatives
may have an increased serotonergic effect when combined with ergot derivatives
may enhance the concentration of serum when combined with ergot derivatives
they increase the concentration of ergot derivatives in serum
it increases the concentration of ergot derivatives in serum
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
may decrease the concentration of serum when combined with methylergometrine
may decrease the concentration of serum when combined with methylergometrine
may decrease the concentration of serum when combined with methylergometrine
may decrease the concentration of serum when combined with methylergometrine
may decrease the concentration of serum when combined with methylergometrine
may enhance the risk of ergot toxicity with CYP3A4 inhibitors
epoetin beta/methoxy polyethylene glycol
may decrease the therapeutic effect of anesthetics
may decrease the therapeutic effect of anesthetics
may decrease the therapeutic effect of anesthetics
may decrease the therapeutic effect of anesthetics
may decrease the therapeutic effect of anesthetics
may decrease the therapeutic effect of anesthetics
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may enhance the serum concentration of Ergot Derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the vasoconstricting effect
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the vasoconstricting effect
it increases the effect of hypertension of ergot derivatives
it increases the effect of hypertension of ergot derivatives
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Ethylenimine
It may diminish the metabolism when combined with Vasodilators
Actions and Spectrum:
It works primarily by stimulating uterine smooth muscle contraction. It acts on the smooth muscle cells of the uterus, causing them to contract and constrict blood vessels. This contraction helps to control bleeding by reducing blood flow and promoting uterine involution (the return of the uterus to its pre-pregnancy state).
methylergometrine is specific to the uterus and has little or no effect on other smooth muscles. Its primary action is on the uterine muscle, making it an effective drug for preventing and treating postpartum hemorrhage and managing bleeding after a miscarriage or abortion.
Frequency not defined
Headache
Diaphoresis
Transient chest pain
Thrombophlebitis
Water intoxication
Hallucinations
Nasal congestion
Diarrhea
Dizziness
Tinnitus
Palpitation
Dyspnea
Hematuria
Leg cramps
Foul taste
Black box warning:
None
Contraindications/caution:
Contraindications:
Caution:
Pregnancy consideration: It is mainly administered during the third stage of labor (after the baby is born) to prevent and treat postpartum hemorrhage, which is excessive bleeding that can occur after childbirth.
Pregnancy Category: C
Lactation: Excretion of the drug in human breast milk is known. Breastfeeding should be delayed for at least 12 hours following the previous dosage.
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
methylergometrine acts as a potent uterotonic agent, stimulating strong and sustained contractions of the uterine muscle. This property prevents and treats postpartum hemorrhage by helping the uterus contract after childbirth.
Pharmacodynamics:
As a uterotonic agent, methylergometrine primarily acts on smooth muscle cells in the uterus and blood vessels, producing specific physiological responses.
Pharmacokinetics:
Absorption
It has a bioavailability of 60% when taken orally (PO) and 78% when administered intramuscularly (IM). The time to reach peak plasma concentration is 30 minutes, regardless of the route of administration (PO, IM, IV).The peak plasma concentration is 3 ng/mL.
Distribution
It has a Vd ranging from 39-73 L, indicating that it is distributed widely throughout the body.
Metabolism
It is primarily metabolized in the liver.
Elimination and Excretion
methylergometrine is excreted in both urine and feces. It has a short half-life of 1 to 5 minutes and a terminal phase of 0.5-2 hours. The drug is rapidly eliminated from the body.
Administration:
Only administer intravenously in an emergency due to the risk of HTN and CVA.
Give more than a minute and monitor the blood pressure and uterine contractions.
Patient information leaflet
Generic Name: methylergometrine
Why do we use methylergometrine?
methylergometrine is a medication with various medical uses, primarily related to its uterotonic and vasoconstrictive properties. Some of the primary uses of methylergometrine include: